PT2197860E - Novos compostos como antagonistas do receptor a1 de adenosina - Google Patents
Novos compostos como antagonistas do receptor a1 de adenosina Download PDFInfo
- Publication number
- PT2197860E PT2197860E PT08835072T PT08835072T PT2197860E PT 2197860 E PT2197860 E PT 2197860E PT 08835072 T PT08835072 T PT 08835072T PT 08835072 T PT08835072 T PT 08835072T PT 2197860 E PT2197860 E PT 2197860E
- Authority
- PT
- Portugal
- Prior art keywords
- optionally substituted
- straight
- branched
- group
- halogen atoms
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 229940124258 Adenosine A1 receptor antagonist Drugs 0.000 title 1
- 239000002598 adenosine A1 receptor antagonist Substances 0.000 title 1
- 125000005843 halogen group Chemical group 0.000 abstract 4
- 125000000217 alkyl group Chemical group 0.000 abstract 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 3
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 2
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000005119 alkyl cycloalkyl group Chemical group 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pulmonology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Vascular Medicine (AREA)
- Psychiatry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Otolaryngology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ES200702643A ES2331220B1 (es) | 2007-10-02 | 2007-10-02 | Nuevos compuestos como antagonistas de los receptores a1 de adenosina. |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT2197860E true PT2197860E (pt) | 2011-08-26 |
Family
ID=40303525
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT08835072T PT2197860E (pt) | 2007-10-02 | 2008-09-30 | Novos compostos como antagonistas do receptor a1 de adenosina |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US8410282B2 (pt) |
| EP (1) | EP2197860B1 (pt) |
| JP (1) | JP5463592B2 (pt) |
| KR (1) | KR101312198B1 (pt) |
| CN (1) | CN101835766B (pt) |
| AT (1) | ATE510829T1 (pt) |
| AU (1) | AU2008306553B2 (pt) |
| BR (1) | BRPI0816554B8 (pt) |
| CA (1) | CA2700526C (pt) |
| CY (1) | CY1112079T1 (pt) |
| DK (1) | DK2197860T3 (pt) |
| EA (1) | EA022473B1 (pt) |
| ES (2) | ES2331220B1 (pt) |
| HR (1) | HRP20110557T1 (pt) |
| MX (1) | MX2010003576A (pt) |
| PL (1) | PL2197860T3 (pt) |
| PT (1) | PT2197860E (pt) |
| SI (1) | SI2197860T1 (pt) |
| WO (1) | WO2009044250A1 (pt) |
| ZA (1) | ZA201002139B (pt) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011076734A1 (en) * | 2009-12-21 | 2011-06-30 | Euroscreen S.A. | Compounds, pharmaceutical composition and methods for use in treating inflammatory diseases |
| EP2941420B1 (en) * | 2013-01-03 | 2018-09-05 | Council of Scientific & Industrial Research | (4e)-4-(4-substituted benzylideneamino)-2,3-dihydro-3- substituted-2-thioxothiazole-5-carbonitriles as a2ar antagonist and process for preparation thereof |
| JP6522602B2 (ja) | 2013-07-02 | 2019-05-29 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | Ｒｏｃｋ阻害剤としての三環式ピリド−カルボキサミド誘導体 |
| CN105492444B (zh) | 2013-07-02 | 2018-09-07 | 百时美施贵宝公司 | 作为rock抑制剂的三环吡啶-甲酰胺衍生物 |
| ES2578363B1 (es) * | 2015-01-22 | 2017-01-31 | Palobiofarma, S.L. | Moduladores de los receptores A3 de adenosina |
| ES2676535B1 (es) * | 2017-01-20 | 2019-04-29 | Palobiofarma Sl | Moduladores de los receptores a3 de adenosina |
| DK3592734T3 (da) | 2017-03-06 | 2021-06-28 | Palobiofarma Sl | Aminsalt af (1r,3s)-3-(5-cyano-4-phenyl-1,3-thiazol-2-ylcarbamoyl)cyclopentancarboxylsyre |
| CN107739350B (zh) * | 2017-09-26 | 2020-12-22 | 天津大学 | 一种合成2-氨基噻唑衍生物的方法 |
| EP3882240A1 (en) | 2020-03-16 | 2021-09-22 | Palobiofarma, S.L. | Cocrystals of (1r,3s)-3-(5-cyano-4-phenyl-1,3-thiazol-2-ylcabamoyl)cyclopentane carboxylic acid |
| EP3957308A1 (en) | 2020-08-21 | 2022-02-23 | Palobiofarma, S.L. | (1r,3s)-3-((5-cyano-4-phenylthiazol-2-yl)carbamoyl)cyclopentane-1-carboxylic acid and derivatives thereof for use in the treatment of airway diseases |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2005510508A (ja) * | 2001-11-08 | 2005-04-21 | 藤沢薬品工業株式会社 | アデノシンアンタゴニストとしてのチアゾールピリダジノン類 |
| SI1466912T1 (sl) * | 2002-01-18 | 2013-08-30 | Astellas Pharma Inc. | Derivat 2-acilaminotiazola ali njegova sol |
| JP2009529059A (ja) * | 2006-03-08 | 2009-08-13 | アキリオン ファーマシューティカルズ，インコーポレーテッド | 抗ｃ型肝炎ウイルス活性を有する置換アミノチアゾール誘導体 |
| WO2007116106A1 (es) * | 2006-04-12 | 2007-10-18 | Palobiofarma, S.L. | Nuevos compuestos como antagonistas de los receptores a1 de adenosina |
-
2007
- 2007-10-02 ES ES200702643A patent/ES2331220B1/es not_active Expired - Fee Related
-
2008
- 2008-09-30 SI SI200830350T patent/SI2197860T1/sl unknown
- 2008-09-30 BR BRPI0816554A patent/BRPI0816554B8/pt active IP Right Grant
- 2008-09-30 CA CA2700526A patent/CA2700526C/en active Active
- 2008-09-30 CN CN2008801126777A patent/CN101835766B/zh active Active
- 2008-09-30 KR KR1020107008768A patent/KR101312198B1/ko active IP Right Grant
- 2008-09-30 DK DK08835072.3T patent/DK2197860T3/da active
- 2008-09-30 US US12/679,941 patent/US8410282B2/en active Active
- 2008-09-30 AT AT08835072T patent/ATE510829T1/de active
- 2008-09-30 WO PCT/IB2008/002556 patent/WO2009044250A1/en active Application Filing
- 2008-09-30 AU AU2008306553A patent/AU2008306553B2/en not_active Ceased
- 2008-09-30 EA EA201000393A patent/EA022473B1/ru not_active IP Right Cessation
- 2008-09-30 JP JP2010527561A patent/JP5463592B2/ja active Active
- 2008-09-30 EP EP08835072A patent/EP2197860B1/en active Active
- 2008-09-30 PL PL08835072T patent/PL2197860T3/pl unknown
- 2008-09-30 ES ES08835072T patent/ES2366075T3/es active Active
- 2008-09-30 PT PT08835072T patent/PT2197860E/pt unknown
- 2008-09-30 MX MX2010003576A patent/MX2010003576A/es active IP Right Grant
-
2010
- 2010-03-25 ZA ZA2010/02139A patent/ZA201002139B/en unknown
-
2011
- 2011-07-26 HR HR20110557T patent/HRP20110557T1/hr unknown
- 2011-08-22 CY CY20111100805T patent/CY1112079T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ZA201002139B (en) | 2011-06-29 |
| US8410282B2 (en) | 2013-04-02 |
| AU2008306553B2 (en) | 2011-06-09 |
| ES2366075T3 (es) | 2011-10-17 |
| AU2008306553A1 (en) | 2009-04-09 |
| CA2700526C (en) | 2014-03-18 |
| BRPI0816554B8 (pt) | 2022-08-30 |
| EP2197860A1 (en) | 2010-06-23 |
| MX2010003576A (es) | 2010-04-22 |
| ES2331220B1 (es) | 2010-09-23 |
| KR101312198B1 (ko) | 2013-09-27 |
| EA201000393A1 (ru) | 2010-08-30 |
| BRPI0816554A2 (pt) | 2015-11-24 |
| ES2331220A1 (es) | 2009-12-23 |
| DK2197860T3 (da) | 2011-08-15 |
| EP2197860B1 (en) | 2011-05-25 |
| KR20100058653A (ko) | 2010-06-03 |
| HRP20110557T1 (hr) | 2011-09-30 |
| SI2197860T1 (sl) | 2011-09-30 |
| CY1112079T1 (el) | 2015-11-04 |
| WO2009044250A1 (en) | 2009-04-09 |
| CN101835766A (zh) | 2010-09-15 |
| CA2700526A1 (en) | 2009-04-09 |
| CN101835766B (zh) | 2013-09-25 |
| BRPI0816554B1 (pt) | 2019-04-09 |
| PL2197860T3 (pl) | 2011-09-30 |
| JP5463592B2 (ja) | 2014-04-09 |
| JP2010540615A (ja) | 2010-12-24 |
| ATE510829T1 (de) | 2011-06-15 |
| US20100311703A1 (en) | 2010-12-09 |
| EA022473B1 (ru) | 2016-01-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201002139B (en) | New compounds as adenosine a1 receptor antagonists | |
| EA201071201A1 (ru) | ИНДОЛЫ В КАЧЕСТВЕ МОДУЛЯТОРОВ НИКОТИНОВОГО РЕЦЕПТОРА АЦЕТИЛХОЛИНА ПОДТИПА α-71 | |
| UA105185C2 (uk) | Піроли | |
| MX2013002558A (es) | Derivado de imidazol de heteroanillo fusionado que tiene efecto de activacion de proteina cinasa activada por monofosfato de adenosina (amk). | |
| WO2008108378A3 (en) | Bicyclic oxomorpholine derivative | |
| EA201170096A1 (ru) | Замещенные производные пиримидона | |
| TN2010000062A1 (en) | Pyrrolidin -2-one derivatives as androgen receptor modulator | |
| MY152281A (en) | 4-pyrimidinesulfamide derivative | |
| MX360667B (es) | Derivados de etinilo como moduladores alostericos del receptor de glutamato metabotropico del subtipo 5 (mglur5). | |
| MY159870A (en) | Piperazine compound capable of inhibiting prostaglandin d synthase | |
| WO2009154754A3 (en) | Synthesis of deuterated morpholine derivatives | |
| EA201071012A1 (ru) | Производные азетидинов, способ их получения и применение их в терапии | |
| MY160882A (en) | Biocidal composition and method | |
| NZ611169A (en) | Pyrazole compounds having therapeutic effect on multiple myeloma | |
| MA32834B1 (fr) | 3-aminocyclopentanecarboxamides servant de modulateurs de recepteurs de chimiokines | |
| UA111950C2 (uk) | Гетероциклічні сполуки для лікування або профілактики розладів, викликаних зниженою нейротрансмісією серотоніну, норепінефрину або допаміну | |
| MX2011009746A (es) | Derivados de n-[(6-aza-biciclo[3.2.1]oct-5-il)-abril-metil]-hetero benzamida, su prepracion y su uso en terapeutica. | |
| IN2012DN01251A (pt) | ||
| ME00929B (me) | NOVI POSTUPAK ZA DOBlJANJE KRISTALNOG OBLIKA V AGOMELATIN A | |
| WO2009130469A8 (en) | Dna-pk inhibitors | |
| MX2012007385A (es) | Derivados de aminoalquilpirimidina como anatagonistas del receptor h4 de histamina. | |
| MX2011010734A (es) | Derivados de indol moduladores del receptor de acetilcolina nicotinico alfa 7 (nachr). | |
| SA515360302B1 (ar) | مركبات رباعي أكسا ثنائي فوسفا سبيرو | |
| MX2009000254A (es) | Nuevos derivados de 1h-indol-1-il-urea, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen. | |
| TW200801016A (en) | Thienopyridine-2-carboxamide derivatives |